In 2021, several companies in the pharmaceutical industry are happy and some are sad, and these pharmaceutical companies have suffered huge losses

 According to the 2021 performance forecasts or flash reports released by various pharmaceutical companies, the past 2021 is also a few happy and a few sorrows for pharmaceutical companies
.
For example, according to the more than 240 A-share pharmaceutical companies that have disclosed their performance forecasts, 13 pharmaceutical companies have a net profit of more than 2 billion yuan, which is gratifying
.
However, 56 pharmaceutical companies also suffered losses
.
According to the 2021 annual performance report disclosed by BeiGene on February 26, the company's total operating income in 2021 increased by 257.
9% year-on-year to 7.
589 billion yuan
.
However, the net profit attributable to the owner of the parent company was a loss of 9.
75 billion yuan, and the net profit attributable to the owner of the parent company after deducting non-recurring gains and losses was a loss of 9.
97 billion yuan; the basic earnings per share was -8.
08 yuan
.
According to statistics, BeiGene has suffered continuous losses in the past four years, with a total loss of 33 billion yuan
.
Among them, from 2018 to 2020, the annual losses of BeiGene were 4.
74 billion yuan, 6.
91 billion yuan and 11.
38 billion yuan respectively
.
Another example is ST Furen’s announcement on January 28, 2022 that Furen Pharmaceutical Group Pharmaceutical Co.
, Ltd.
expects a loss of about 1.
5 billion to 1.
8 billion yuan in net profit attributable to shareholders of listed companies in 2021; the company expects that in 2021 Realizing the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses will result in a loss of about 400 million to 700 million yuan
.
It is reported that ST Fu Jen has continued to perform poorly
.
According to ST Fu Jen's 2021 semi-annual report and third quarter report, in the first half of 2021, the company's revenue decreased by 32.
65% year-on-year to 902 million yuan; the net profit attributable to shareholders of the listed company was -294 million yuan, which was attributable to the listed company.
The non-net profit deducted by the company's shareholders was -296 million yuan; the company's revenue in the first nine months of 2021 decreased by 37.
02% year-on-year to 1.
28 billion yuan, and the net profit was -532 million yuan
.
According to the performance forecast released by Hainan Haiyao on January 29, 2022, its expected operating income in 2021 will be 1.
8 billion to 2.
2 billion yuan; the net profit attributable to shareholders of listed companies will be -1.
65 billion to -1.
4 billion yuan, a year-on-year loss.
Expanded; net profit after deducting non-recurring gains and losses was -1.
4 billion to -1.
2 billion yuan, a year-on-year loss widening; earnings per share were -1.
2718 to -1.
0791 yuan
.
Regarding the reasons for the changes in its performance, the company stated that (1) the gains and losses from changes in fair value decreased year-on-year
.
(2) The amount accrued for credit impairment losses increased year-on-year
.
(3) The amount accrued for asset impairment losses increased year-on-year
.
(4) R&D expenses increased year-on-year
.
Among them, in terms of research and development expenses, during the reporting period, the company's research and development expenses amounted to about 194 million yuan, an increase of about 68 million yuan compared with 126 million yuan in the same period of the previous year
.
The main reason is that the company has increased capital investment in clinical research of flufenidone capsules, phase I clinical research of raw materials and preparations of Pinegarbine, and development of cochlear implant technology, resulting in an increase in the amount of research and development expenses
.
In addition, on February 25, China Cell released the 2021 performance report.
According to the report, China Cell's annual revenue of 134 million yuan in 2021, all from the recombinant eight-factor product "Anjiain"
.
But in the short term, "An Jiain" failed to save the loss-making China Cell
.
The performance report shows that the loss of China Cell in 2021 is still expanding, reaching 867 million yuan, and the loss has increased by 21.
66%
.
A large amount of R&D investment, marketing promotion, and personnel compensation are all reasons for the loss
.
In addition to the above companies, ST National Medical expects a net profit loss of 735 million-825 million yuan attributable to shareholders of listed companies in 2021, and a non-net profit loss of 650 million to 750 million yuan.
If the new management due to equity incentives is deducted this year Expenses, after deducting non-fee losses, narrowed year-on-year; achieved operating income of 2.
9 billion to 2.
95 billion, a year-on-year increase of about 80%
.
Erkang Pharma expects that the net profit attributable to shareholders of listed companies will be 650 million yuan to 820 million yuan in 2021, which will turn from profit to loss compared with the same period of the previous year.
-798 million yuan
.
Maiwei Bio predicts that the net profit attributable to owners of the parent company in 2021 will be -772 million yuan, and the net profit attributable to owners of the parent company after deducting non-recurring gains and losses will be -775 million yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.